Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: RO6889450
- drug: Placebo
Eligibility
Inclusion Criteria:
- Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini
International Neuropsychiatric Interview (MINI)
- Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure
D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no
more than two antipsychotics
- Medically stable during the 3 months prior to study entry
- Participant is an outpatient with no psychiatric hospitalizations within the prior 6
months
- PANSS negative symptom factor score of 18 or higher
- The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness),
P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6
(suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse
control)
- Has an informant who is considered reliable by the Investigator
- Body mass index (BMI) between 18-40 kg/m2 inclusive
- Female participants are eligible to participate if not pregnant, not breastfeeding and
agree to remain abstinent or use acceptable contraceptive methods during the treatment
period and for at least 28 days after the last dose of study drug
Exclusion Criteria:
- Moderate to severe substance use disorder within six months of study entry (excluding
nicotine or caffeine) as defined by DSM-5
- Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
- Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
- PANSS item G6 (depression) greater than or equal to 5
- Significant risk of suicide or harming him- or herself or others according to the
Investigator's judgment
- A prior or current general medical condition that might be impairing cognition or
other psychiatric functioning
- Positive result at screening for hepatitis B surface antigen (HBsAg), hepatitis C
(HCV), or HIV-1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA
is negative
- Tardive dyskinesia that is moderate to severe or requires treatment
- History of neuroleptic malignant syndrome
- Average triplicate Fridericia's Correction Formula (QTcF) interval greater than 450
milliseconds (msec) for males and 470 msec for females or other clinically significant
abnormality on screening electrocardiogram (ECG) based on centralized reading
- Clinically significant abnormalities in laboratory safety test results
- Significant or unstable physical condition that in the investigator's judgment might
require a change in medication or hospitalization during the course of the study
- On more than one antidepressant, or if on one antidepressant, a change in dose within
28 days prior to screening
- History of clozapine treatment
- History of treatment with electroconvulsive therapy (ECT)
- Concomitant use of prohibited medications
- Positive urine drug screen for amphetamines, methamphetamines, opiates,
buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
- Receipt of an investigational drug within 28 days or five times the half-life of the
investigational drug (whichever is longer) before the first study drug administration
- Donation of blood over 400 mL within 3 months prior to screening
- Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening
or during screening. Participants can be re-screened after 4 weeks of full recovery in
addition to Investigator and/or institutional approval to enroll
Ages Eligible for Study
18 Years - 55 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting